Susan Bal

Jan 16, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Susan Bal

You've successfully added Hematology Oncology: Myeloma to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Jan 3, 2024 | cancernetwork.com | Susan Bal

Treatment with BMS-986393 (CC-95266), a GPRC5D-targeted CAR T-cell therapy, appeared to yield significant efficacy and limited, self-resolving toxicity among patients with relapsed/refractory multiple myeloma, according to Susan Bal, MD, in a conversation with CancerNetwork® on data from a phase 1 trial (NCT04674813).1 At the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition, Bal, an assistant professor of Medicine and Hematology & Oncology at The University of Alabama...

Dec 22, 2023 | targetedonc.com | Susan Bal

GPRC5D is a receptor expressed on multiple myeloma cells and is considered a promising therapeutic target. The FDA-approved drug talquetamab (Talvey), a T-cell engager targeting GPRC5D, has shown positive results in treating relapsed myeloma. While GPRC5D's potential is present, questions remain regarding its optimal treatment approach within the evolving myeloma treatment landscape.

Dec 10, 2023 | onclive.com | Susan Bal

December 10, 2023Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Nov 14, 2023 | nature.com | Susan Bal |Luciano Costa |Muzaffar H. Qazilbash |Shaji Kumar

Dear Editor,Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by abnormal immunoglobulin light chain production, which forms insoluble fibrillary aggregates that deposit in tissues causing end-organ dysfunction. Cardiac involvement predominantly drives early mortality and influences patients’ functional status, treatment choice, and prognosis [1]. The management of AL amyloidosis focuses on clone eradication using plasma cell-directed therapies.